Cancerimmunterapi

Julie Westerlin Kjeldsen; Marco Donia; Inge Marie Svane

Cancerimmunterapi

Translated title of the contribution: Cancer immunotherapy

Julie Westerlin Kjeldsen, Marco Donia, Inge Marie Svane

Department of Clinical Medicine

1 Citation (Scopus)

Abstract

Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.

Translated title of the contribution	Cancer immunotherapy
Original language	Danish
Article number	V09170691
Journal	Ugeskrift for Laeger
Volume	180
Number of pages	5
ISSN	0041-5782
Publication status	Published - 21 May 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/cancerimmunterapi

Cite this

@article{74d710278434407396b7ee55984e0a95,

title = "Cancerimmunterapi",

abstract = "Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.",

author = "Kjeldsen, {Julie Westerlin} and Marco Donia and Svane, {Inge Marie}",

year = "2018",

month = may,

day = "21",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Cancerimmunterapi

AU - Kjeldsen, Julie Westerlin

AU - Donia, Marco

AU - Svane, Inge Marie

PY - 2018/5/21

Y1 - 2018/5/21

N2 - Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.

AB - Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.

M3 - Tidsskriftartikel

C2 - 29804567

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V09170691

ER -

Cancerimmunterapi

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this